Chemomab Therapeutics Ltd. (CMMB) is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapeutics for unmet medical needs in inflammation and fibrosis diseases. This Israeli biotech company primarily focuses on the research and development of monoclonal antibodies, a form of drug therapy that is currently revolutionizing the management of these diseases.
The work of Chemomab is underpinned by its proprietary platform technology, which allows for the identification of unique disease targets in a wide range of conditions associated with inflammation and fibrosis. This includes illnesses such as non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and systemic sclerosis (SSc). The company's leading drug candidate, CM-101, is a monoclonal antibody being developed to treat these potentially life-threatening conditions.
Dr. Adi Mor and Dr. Moshit Yarden co-founded Chemomab Therapeutics Ltd. in 2011. As a key intersection of molecular biology, antibody engineering, and medicinal chemistry, the company is positioned to impact the lives of many patients who suffer from inflammatory and fibrotic diseases. Chemomab's team comprises experienced and passionate professionals dedicated to translating cutting-edge scientific discoveries into breakthrough therapies.
Since its establishment, Chemomab has been committed to scientific excellence and credibility. It conducts rigorous preclinical and clinical testing to ensure the safety and efficacy of its therapeutic candidates. The company's strategies also include early and proactive engagement with regulatory bodies to guarantee that its product development processes meet international safety and ethical standards.
In addition to its proprietary platform technology, Chemomab's strength lies in its deep-seated understanding of the molecular pathways that drive inflammation and fibrosis. This detailed knowledge enables the design of highly specific and highly effective intervention strategies, ensuring that the company's therapeutics can provide significant benefit to patients.
Chemomab Therapeutics is publicly traded on the NASDAQ under the ticker symbol 'CMMB'. This has given the company the opportunity to generate revenue for further research and development, and to engage with a global network of investors and stakeholders in its mission to tackle unmet medical needs. Always pushing the boundaries of science and medicine, Chemomab Therapeutics Ltd. continues to strive for greater developments to offer a promising future for patients living with inflammatory and fibrotic diseases.